A.J. Rice

How much is being driven by this discussion versus just the general market environment?

Were those, I know those don't happen overnight. Were those largely contemplated when you made your comments about the outlook in the third quarter

I'm getting back of the envelope that, that probably generates EPS growth of roughly mid-single digits, 5% to 6%

You have insight on what's happening into those markets, and that's probably the biggest pressure point for commercial trends these days. And that insight is not something that, for example, your b...

you're well into the PBM selling season. And you're gearing up to talk about benefit design with your commercial clients and the broader healthcare coverage

I'm trying to figure out how much, what is the underlying assumption around what that does to the earnings outlook of the company

maybe the MLR and Medicaid is trending a little better. Is that primarily due to the flu and weather that you're calling out

How easy is it to notify them that now it may make sense to re-sign up? And what efforts do you have in place for that

you guys had sized your estimate of what the headwind would be if the public exchange subsidies, enhanced subsidies were to go away at about a dollar a share

are you seeing it return to sort of your normal low-single digit cost trend or is it still somewhat elevated on just an apples-to-apples year-over-year basis

You talk about a decrease year-to-year in health benefit expense, pharmaceutical cost, and then on the G&A line, professional fees, was the -- was that sort of as expected?

is there any way to sort of size some of the opportunities you see? And are those being reflected now in operating results?

Is it just a financial investment from your side? Are you going to do things operationally that might make a difference for you?

what are you seeing in disease progression with someone that has kidney disease time to get to dialysis?

do they have impact on the adjusted earnings? Maybe cyber-attack, what was the earnings and volume impact in the quarter that you estimate specifically to that event?

you said the cyberattack also had an impact on revenue per treatment. I really wasn't -- maybe I'm missing something that's obvious

can you maybe give us a little more of what happened and why do you think that's a pull forward versus potentially a better trend

Any update on Brazil and maybe more broadly on the M&A pipeline, what you're seeing

you still feel like I know we've got volatility quarter-to-quarter, but you're on track for a breakeven by '27 in that business?

do you have a figure for what you think you will do on share repurchases? Any comments on the deal pipeline

Is there any change in significant change in the way you are looking at the growth in patient treatment costs versus what you saw in 2024?

Are you hearing anything different in terms of the amount of activity that you're seeing out there

I wondered if I could just get you to comment on are you assuming sort of a similar cost trend in '26 in your embedded guidance to what you experienced in '25

When you're in your dialogue with the states, are they acknowledging that? Are they seeing you as being unique relative to other players in that trend

Can you size a little bit for us? Or give us a sense about how much the relative impact of each of those is in the guidance revision

Are you seeing anything unusual there? There's concern about the IRA impact. How is that shaping up so far relative to the changes

Is that fully reflective of which you've got the full view of open enrollment at this point? So you think from here, it's just agents largely

the right way -- am I hearing you say, you basically had $180 million of negative impact from flu and weather in the first quarter

update us on where you're at with the AI initiatives? And is that $400 million a pretty firm number

can you talk about the expense items SWB, supplies, other operating expenses, professional fees, etcetera. What are your underlying assumptions there that are embedded in the guidance?

there's been some chatter and some of the managed care companies are talking about anticipating a potential step-up in volumes in the fourth quarter, elective procedures

you raised your EBITDA guidance, adjusted EBITDA by about $300 million at the midpoint. I think that's roughly the amount of outperformance that you saw -- seen so far year-to-date

The revenue per adjusted admission up 2.9%, I think. It was strong, especially with surgeries off. Can you parse out a little bit more whether that was year-to-year improvement in DPP programs

where are you at in your pricing for 2025, 2026? Anything new or different you're seeing in terms of utilization review, denial rates, anything along those lines?

how much incremental information given the initiatives you have that you feel like you have to sort of get ahead of what normally shows up in the second quarter?

in your '26 outlook, how much of that will you have realized this year, if any

do you have any feel for where the overall market is? You said in your comments that where there's planned exits, you're not picking up disproportionate numbers

you continue to grow that membership on the value-based primary care side and seem to be hitting your metrics there

is there any high level comments you can make about whether the trajectory's changed, your optimism about the progression you can make in '26, '27, and '28

There's discussion about 2027 payment year. It sounds sort of cautious about that, but then 2028 sounds like the year where you think the investments you're making will bear fruit

Can you parse those out and give us a sense of what the core grew on an EBITDA basis in the acute side, possibly? And then, on AI use cases that Marc called out, can you pick two or three that are ...

how do you think about how that translates into operating performance in terms of financial impact of those applications?

Give us any flavor on what's embedded in pricing? Is it more of the same what you saw this year across the 2 segments?

there's about $25 million of sort of miscellaneous DPP payments. And it seemed like in the back half of the year that are incremental, is that more in the third quarter?

your pricing on both businesses, actually, even if you ex out the DPP payments was pretty strong by historic standards. Anything to call out there?

Just wondering if you see that impacting discussions with the MCOs at all on either Medicare Advantage, commercial, whatever

Washington, D.C. was a big one for you that was still pending. Any update there?

Are you seeing any of the states that you're in tweak the base payment rate

about the possibility of moving the provider tax limit from 6% to 5%. Have you guys looked at that?

can you just flush out some of the key assumptions you've got in coming up with that number and how much variability you think there might be around that

Do they draw away from your existing facility's enough to to impact the same store trends

can we focus in on is it running close to 10% or is it more in the 7% to 8%?

Can you just sort of comment a little more deeply on your view of where Optum Insight sits competitively at this point?

I would assume that has some trickle-down benefit to Optum Health or when you're talking about having margin consistent with this year, next year on the position piece

it sounds like you're saying most of the elevated care that you're seeing is on the group side

Was there anything that changed in those - the intensity of any of those trends? And anything -- any unusual items in there that impacted the results